Affluence Corporation (AFFU): There you go... AFFU will not go anywher...

There you go... AFFU will not go anywhere

TJG · 2024-11-19T12:06:22.3670000Z

There you go... AFFU will not go anywhere but there will be a transition in the business which AI defines as The OTC calls it Change of Control In building a business, a "transition" refers to a significant change in the ownership, leadership, or operational structure of a company, often occurring when a business moves from one phase of its lifecycle to another, such as from startup to growth, or when a founder decides to retire or sell the company to new owners; it involves a planned process to manage this change and ensure smooth continuity within the organization

Play Episode

7min

Proactive - Interviews for investors

Tolu Minerals CEO reveals 8 new targets at Mt Pence and talks initial gold production at Tolukuma

Tolu Minerals Ltd CEO Iain Macpherson talked with Proactive about the company’s initial gold production at the Tolukuma Gold Mine in Papua New Guinea. While not commercial output yet, Macpherson explained that gold from commissioning demonstrates proof of concept and marks the start of larger-scale activity. The company is leveraging existing infrastructure valued at around AU$500 million, with a strategy focused on addressing previous cost pressures that led to mine closure. “The mine shut down, not because the resource ran out... but because they were faced with severe cost pressures,” Macpherson said, citing diesel dependence and lack of road access. Macpherson highlighted Tolu’s capital program and extensive exploration footprint across the broader Tolukuma structure. He detailed the utility of airborne magnetotelluric (MT) surveys, which provide deep, three-dimensional geophysical data. “It gives you a very good three-dimensional picture... and enhances target generation,” he said, noting this method’s success in similar geologies globally. The company also discussed its Mt Penck project on New Britain Island, revealing the identification of eight new porphyry targets based on the MT survey. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications for future content. #ToluMinerals #GoldMining #ASXTOK #PapuaNewGuinea #Tolukuma #GoldExploration #MiningStocks #PorphyryTargets #MTsurvey #JuniorMining #GoldProduction #InvestorUpdates #MiningNews

Proactive - Interviews for investors

NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate

NanoViricides Chief Financial Officer Meeta Vyas joined Steve Darling from Proactive to share updates on the company’s development of broad-spectrum antiviral therapeutics and its unique positioning amid global market uncertainty. Vyas emphasized that NanoViricides, headquartered in Shelton, Connecticut, conducts all of its research and development in-house, which insulates the company from international tariff fluctuations and supply chain disruptions. At the center of the company’s pipeline is NV-387, a broad-spectrum antiviral drug that differs from vaccines in both function and strategy. Rather than targeting specific viral strains, NV-387 works by mimicking the receptor sites used by over 90% of pathogenic viruses—including influenza, RSV, COVID-19, and smallpox. Vyas explained that this approach helps circumvent the problem of viral mutation, which often renders traditional vaccines less effective. “Regardless of how they mutate, they land on the same receptor site. So we copy the receptor site, which is invariant to mutation,” she said, underscoring the robustness of the NanoViricides platform. She also highlighted supportive regulatory developments in the U.S., noting that the new HHS administration has endorsed a more integrated approach to pandemic preparedness, which includes therapeutics like NV-387 as a key component. In light of recent USDA funding initiatives aimed at combating H5N1 avian flu, Vyas said the company is keen to explore applications of NV-387 in that space as well. Currently, NanoViricides is conducting a Phase 2 clinical trial targeting smallpox, following successful Phase 1 results with no reported adverse effects. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc NV387 #BroadSpectrumAntiviral #BiotechStocks #AntiviralTherapeutics #SmallpoxTreatment #BirdFlu #RSV #COVID19Treatment #ProactiveInvestors #PharmaInnovation #MeetaVyas #HHS #PandemicPreparedness

Proactive - Interviews for investors

Orion Minerals CEO on Prieska & Okiep DFS milestones as company enters next phase

Orion Minerals Ltd (ASX:ORN, JSE:ORN) managing director and CEO Errol Smart talked with Proactive's Stephen Gunnion about the completion of definitive feasibility studies (DFS) for both the company’s flagship Prieska copper-zinc project and the Flat Mines project at its Okiep copper project. Smart described this as a pivotal moment, noting, “It’s taken us eight years now to put them together… but it's really a great outcome for us.” The studies confirm robust development pathways for both operations in South Africa's Northern Cape, with both projects fully permitted and development-ready. Smart said Orion is in a unique position globally, with capital intensity figures below key industry benchmarks. The combined production profile is expected to deliver 30,000 tonnes of copper annually at around $9,500 per tonne capital intensity, placing the company in the lower quartile of the cost curve. The Prieska project will follow a two-phase development plan, with a modest $25 million start-up operation set to begin production within 13 months, followed by a ramp-up to full-scale output. Smart also confirmed that discussions are underway with strategic partners, including the Industrial Development Corporation and offtake-related financiers. He highlighted that smelters and traders are actively seeking long-term copper supply, saying, “We represent a very interesting opportunity for them, with certainty.” Visit Proactive’s YouTube channel for more company updates and interviews. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #OrionMinerals #CopperMining #PrieskaProject #OkiepProject #BaseMetals #MiningInvestment #FeasibilityStudy #SouthAfricaMining #CopperProduction #ZincProduction

Proactive - Interviews for investors

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones

Trevi Therapeutics CEO Jennifer Good joined Steve Darling from Proactive to discuss the company’s progress in advancing its cough treatment pipeline using nalbuphine, a mixed agonist-antagonist opioid. Originally developed for acute indications, nalbuphine is now being repurposed due to its dual mechanism of action, working both peripherally in the lungs and centrally in the brainstem, offering a novel approach to treating chronic cough disorders. Trevi initially explored multiple indications, including skin conditions caused by severe itching and neurological cough. However, compelling clinical data led the company to focus on cough-related indications. Good explained, “We thought our drug was different because not only does it work peripherally in the lung, it works centrally at the brain, which mediates coughing and breathing.” The company is now targeting three key areas: interstitial lung diseases (including idiopathic pulmonary fibrosis, or IPF), refractory chronic cough (RCC), and other neurological cough conditions. Following promising Phase 2a results in RCC—an area where many previous drug candidates have failed—Trevi is preparing for a Phase 2b dose-ranging study. If successful, only one pivotal study may be required before regulatory filing. Good also highlighted Trevi’s strong financial position, noting that the company has sufficient cash runway to support its current studies through the second half of 2026, including further development in RCC and IPF. #proactiveinvestors #trevitherapeuticsinc #nasdaq #trvi #JenniferGood #Nalbuphine #ChronicCough #RefractoryCough #Phase2aResults #BiotechNews #PharmaPipeline #IPF #ClinicalTrials #CoughTreatment #NeurologicalDisorders #ProactiveInvestors

Followers	606
Posts	29457
Boards Moderated	3
Alias Born	06/20/2007

Volume:	-
Day Range:
Bid:	0.0002
Ask:	0.0004
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

AFFU Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free